Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

Biotechguy21 Jan. 17 at 11:16 AM

$AGEN this POS can spend that in 45 days. Try harder Joecuck. You can do it 🤡🤡😂😂💰💰

0 · Reply

Doom_Gloom_AR Jan. 17 at 1:17 AM

$AGEN https://www.ajmc.com/view/france-expands-bot-bal-immunotherapy-access-for-ovarian-cancer-and-soft-tissue-sarcoma https://firstwordpharma.com/story/7066578

0 · Reply

joechuck71 Jan. 17 at 12:52 AM

$AGEN Net proceeds 65,945 Cash held in escrow (7,500) (c) Net cash received at closing $ 58,445 + 7.5 mil 65,945 and add the bank bal 4 mil round it off to 70 mil not bad and paid off everyone. next they start placing orders for bot/bal and zydus starts paying us up to 50mil we have 30 mil CA land 21 mil in mink stock

1 · Reply

manny11419 Jan. 17 at 12:44 AM

$AGEN We got a big bonus this year...the Simon two staged design HCC trial. bot/bal vs Ipi/nivo..this is a biggie. Should get data second half.

1 · Reply

WhiteBreeze Jan. 16 at 11:17 PM

$AGEN manipulating space time is cool but i need more people to learn because i cant be everywhere at once ..

0 · Reply

WhiteBreeze Jan. 16 at 10:32 PM

$SPY $AGEN

0 · Reply

WhiteBreeze Jan. 16 at 10:26 PM

$AGEN You know why I’m not afraid of the dark. Because I am the scariest thing in it.

0 · Reply

WhiteBreeze Jan. 16 at 10:21 PM

$AGEN my old friend pain

0 · Reply

WhiteBreeze Jan. 16 at 10:17 PM

$AGEN If you see someone with their hand out the red mustang window enjoying this 30 degrees that’s me ..

0 · Reply

BillyBobBleach Jan. 16 at 9:12 PM

$AGEN there will be a massive reversal soon

0 · Reply

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Jan 15, 2026, 7:01 AM EST - 1 day ago

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Jan 12, 2026, 7:30 AM EST - 4 days ago

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

$Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC$

Dec 23, 2025, 8:05 AM EST - 24 days ago

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Dec 4, 2025, 1:43 AM EST - 6 weeks ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Nov 19, 2025, 4:01 PM EST - 2 months ago

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Nov 18, 2025, 8:41 AM EST - 2 months ago

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Nov 10, 2025, 7:30 AM EST - 2 months ago

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Nov 5, 2025, 1:47 PM EST - 2 months ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

$Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025$

Oct 17, 2025, 8:00 AM EDT - 3 months ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 16, 2025, 7:48 AM EDT - 3 months ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

$France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer$

Sep 9, 2025, 7:43 AM EDT - 4 months ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 5, 2025, 8:52 AM EDT - 4 months ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 2:04 PM EDT - 5 months ago

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Aug 26, 2025, 9:37 AM EDT - 5 months ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 19, 2025, 7:30 AM EDT - 5 months ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 11, 2025, 7:30 AM EDT - 5 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Jul 31, 2025, 7:30 AM EDT - 6 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

$Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025$

Jul 25, 2025, 12:46 PM EDT - 6 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

$Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3$

Jul 7, 2025, 8:55 AM EDT - 6 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jun 17, 2025, 7:30 AM EDT - 7 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 7 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 4, 2025, 2:38 PM EDT - 8 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 3, 2025, 7:00 AM EDT - 8 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 8 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 23, 2025, 3:09 PM EDT - 8 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 15, 2025, 10:40 AM EDT - 8 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 2:46 PM EDT - 8 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:30 AM EDT - 8 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 8 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Apr 29, 2025, 7:30 AM EDT - 9 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 9 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 9 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 9 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Mar 25, 2025, 4:40 PM EDT - 10 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 19, 2025, 7:30 AM EDT - 10 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 11, 2025, 10:39 AM EDT - 11 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 11 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Feb 26, 2025, 4:48 PM EST - 11 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 25, 2025, 2:30 PM EST - 11 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 8:26 AM EST - 11 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:33 AM EST - 11 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 11 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

$Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas$

Jan 29, 2025, 12:37 PM EST - 1 year ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 22, 2025, 2:48 PM EST - 1 year ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Dec 18, 2024, 7:30 AM EST - 1 year ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 5, 2024, 7:30 AM EST - 1 year ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Nov 27, 2024, 8:15 AM EST - 1 year ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 12, 2024, 10:41 AM EST - 1 year ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Biotechguy21 Jan. 17 at 11:16 AM

$AGEN this POS can spend that in 45 days. Try harder Joecuck. You can do it 🤡🤡😂😂💰💰

0 · Reply

Doom_Gloom_AR Jan. 17 at 1:17 AM

$AGEN https://www.ajmc.com/view/france-expands-bot-bal-immunotherapy-access-for-ovarian-cancer-and-soft-tissue-sarcoma https://firstwordpharma.com/story/7066578

0 · Reply

joechuck71 Jan. 17 at 12:52 AM

1 · Reply

manny11419 Jan. 17 at 12:44 AM

$AGEN We got a big bonus this year...the Simon two staged design HCC trial. bot/bal vs Ipi/nivo..this is a biggie. Should get data second half.

1 · Reply

WhiteBreeze Jan. 16 at 11:17 PM

$AGEN manipulating space time is cool but i need more people to learn because i cant be everywhere at once ..

0 · Reply

WhiteBreeze Jan. 16 at 10:32 PM

$SPY $AGEN

0 · Reply

WhiteBreeze Jan. 16 at 10:26 PM

$AGEN You know why I’m not afraid of the dark. Because I am the scariest thing in it.

0 · Reply

WhiteBreeze Jan. 16 at 10:21 PM

$AGEN my old friend pain

0 · Reply

WhiteBreeze Jan. 16 at 10:17 PM

$AGEN If you see someone with their hand out the red mustang window enjoying this 30 degrees that’s me ..

0 · Reply

BillyBobBleach Jan. 16 at 9:12 PM

$AGEN there will be a massive reversal soon

0 · Reply

Overcrumb Jan. 16 at 9:10 PM

$AGEN a biotech analyst once stated on a blog- “ it’s always tomorrow “ with Agenus. This was September 2022, 3 1/2 YEARS AGO. Rings true today. Always tomorrow- always always always…..

0 · Reply

WhiteBreeze Jan. 16 at 9:09 PM

$AGEN now the lead singer of my band is out sick and i gotta step up for out gig….

0 · Reply

DownATon Jan. 16 at 8:41 PM

$AGEN so they reported 75 million up front but it was really only 58 million everytime you want to give garo the benefit of the doubt , he pulls this crap he really is a criminal

1 · Reply

elmono Jan. 16 at 8:35 PM

$AGEN that obviously turned out differently than I expected 😵‍💫🤷‍♂️

0 · Reply

BakerBrother Jan. 16 at 8:31 PM

$AGEN Medpace has had posession for over a year but due recently concluded legal proceedings was probably not able to sell until yesterday. Market makers obviously know this before we do and will hit the stock price down sloppily to shake shares lose so they can cover at the bottom. That’s how this works.

1 · Reply

BakerBrother Jan. 16 at 8:18 PM

$AGEN my guess is it’s the Medpace shares

3 · Reply

pedmac2000 Jan. 16 at 8:10 PM

$AGEN wtf ?? Is going! On!!!

0 · Reply

HarryA123 Jan. 16 at 7:36 PM

$AGEN Looks shitty

0 · Reply

neversurrender2024 Jan. 16 at 7:35 PM

$AGEN another gsk -qs21 type deal give away.... onr blunder after the next ....

0 · Reply

Miracleshappen Jan. 16 at 7:35 PM

$AGEN What’s going on here. Crashing after recent articles about positive news. Is this investment worthy or manipulative junk?

0 · Reply

neversurrender2024 Jan. 16 at 7:26 PM

$AGEN so garos track record of incompetence moves foward!

1 · Reply

weichsel1 Jan. 16 at 7:23 PM

$AGEN Another heavy volume down day, on news that was long expected. The sale should substantially cut the corporate burn rate.

1 · Reply

Market Cap	125.15M
Revenue (ttm)	103.46M
Net Income (ttm)	-227.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-219.61%
Debt to Equity Ratio	-0.12

Volume	1,737,400
Avg Vol	689,462
Day's Range	N/A - N/A
Shares Out	34.01M
Stochastic %K	6%
Beta	1.58
Analysts	Sell
Price Target	$12.33